- Report
- October 2019
- 128 Pages
Global
From €10600EUR$10,995USD£9,066GBP
- Report
- March 2021
- 52 Pages
Global
€1271EUR$1,318USD£1,087GBP
- Report
- September 2020
- 65 Pages
Global
€1271EUR$1,318USD£1,087GBP
- Report
- April 2022
- 188 Pages
Global
From €3471EUR$3,600USD£2,968GBP
- Report
- March 2020
- 90 Pages
Asia Pacific
From €1446EUR$1,500USD£1,237GBP
- Drug Pipelines
- May 2018
- 79 Pages
Global
From €1928EUR$2,000USD£1,649GBP
- Report
- August 2018
- 24 Pages
Global
From €2410EUR$2,500USD£2,061GBP
- Report
- April 2023
- 113 Pages
Global
€3374EUR$3,500USD£2,886GBP
- Report
- August 2019
- 140 Pages
Global
From €3856EUR$4,000USD£3,298GBP
- Report
- April 2018
United States
From €7708EUR$7,995USD£6,592GBP
- Newsletter
- May 2024
- 3 Pages
Europe
From €126EUR$131USD£108GBP
- Drug Pipelines
- August 2018
- 610 Pages
Global
From €21210EUR$22,000USD£18,140GBP
- Report
- August 2018
- 94 Pages
Global
From €9641EUR$10,000USD£8,245GBP
- Drug Pipelines
- July 2018
- 503 Pages
Global
From €21210EUR$22,000USD£18,140GBP
- Report
- January 2024
- 95 Pages
Global
From €3500EUR$3,889USD£3,098GBP
- Report
- January 2024
- 87 Pages
Global
From €3500EUR$3,889USD£3,098GBP
- Report
- April 2023
- 97 Pages
Global
From €3500EUR$3,889USD£3,098GBP
- Report
- April 2023
- 82 Pages
Global
From €3500EUR$3,889USD£3,098GBP
- Report
- January 2021
- 138 Pages
China, Global
From €3000EUR$3,333USD£2,656GBP
- Report
- July 2023
- 87 Pages
Global
From €3500EUR$3,889USD£3,098GBP
Adalimumab is a biologic drug used to treat a variety of immune disorders, including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, and juvenile idiopathic arthritis. It is a monoclonal antibody that works by blocking the action of tumor necrosis factor (TNF), a protein that plays a role in inflammation. Adalimumab is administered by subcutaneous injection and is available in both brand-name and generic forms.
Adalimumab is one of the most widely prescribed drugs for immune disorders, and it has been approved for use in more than 100 countries. It is a highly effective treatment for many of the conditions it is used to treat, and it has been shown to improve quality of life for patients.
Some of the companies in the Adalimumab market include AbbVie, Amgen, Biogen, Boehringer Ingelheim, Janssen Biotech, Merck, and Pfizer. Show Less Read more